ORMP Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Oramed Pharmaceuticals's net margin of -49.65%. Oramed Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Oramed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 37.71%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 557.2%. Given that NovaBay Pharmaceuticals has higher upside potential than Oramed Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Oramed Pharmaceuticals.

Oramed Pharmaceuticals has a beta of 1.697, which suggesting that the stock is 69.699% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Oramed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Oramed Pharmaceuticals's net income of -$19.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Oramed Pharmaceuticals's price-to-earnings ratio is 21.45x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals is 36.14x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Oramed Pharmaceuticals's net margin of -2357.27%. Oramed Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Oramed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 37.71%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Oramed Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Oramed Pharmaceuticals.

Oramed Pharmaceuticals has a beta of 1.697, which suggesting that the stock is 69.699% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Oramed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Oramed Pharmaceuticals's net income of -$19.6M is lower than Palatin Technologies's net income of -$7.8M. Notably, Oramed Pharmaceuticals's price-to-earnings ratio is 21.45x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals is 36.14x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Scilex Holding has a net margin of -- compared to Oramed Pharmaceuticals's net margin of -229.58%. Oramed Pharmaceuticals's return on equity of -- beat Scilex Holding's return on equity of --.

Oramed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 37.71%. On the other hand Scilex Holding has an analysts' consensus of $9.08 which suggests that it could grow by 2115.45%. Given that Scilex Holding has higher upside potential than Oramed Pharmaceuticals, analysts believe Scilex Holding is more attractive than Oramed Pharmaceuticals.

Oramed Pharmaceuticals has a beta of 1.697, which suggesting that the stock is 69.699% more volatile than S&P 500. In comparison Scilex Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Oramed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scilex Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals pays -- of its earnings as a dividend. Scilex Holding pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals quarterly revenues are --, which are smaller than Scilex Holding quarterly revenues of $16.4M. Oramed Pharmaceuticals's net income of -$19.6M is higher than Scilex Holding's net income of -$37.6M. Notably, Oramed Pharmaceuticals's price-to-earnings ratio is 21.45x while Scilex Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals is 36.14x versus 0.93x for Scilex Holding. Usually stocks with elevated PS ratios are considered overvalued.

Skye Bioscience has a net margin of -- compared to Oramed Pharmaceuticals's net margin of --. Oramed Pharmaceuticals's return on equity of -- beat Skye Bioscience's return on equity of --.

Oramed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 37.71%. On the other hand Skye Bioscience has an analysts' consensus of -- which suggests that it could grow by 576.69%. Given that Skye Bioscience has higher upside potential than Oramed Pharmaceuticals, analysts believe Skye Bioscience is more attractive than Oramed Pharmaceuticals.

Oramed Pharmaceuticals has a beta of 1.697, which suggesting that the stock is 69.699% more volatile than S&P 500. In comparison Skye Bioscience has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.874%.

Oramed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals pays -- of its earnings as a dividend. Skye Bioscience pays out -- of its earnings as a dividend.

Oramed Pharmaceuticals quarterly revenues are --, which are smaller than Skye Bioscience quarterly revenues of --. Oramed Pharmaceuticals's net income of -$19.6M is lower than Skye Bioscience's net income of -$3.9M. Notably, Oramed Pharmaceuticals's price-to-earnings ratio is 21.45x while Skye Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals is 36.14x versus 270.03x for Skye Bioscience. Usually stocks with elevated PS ratios are considered overvalued.